Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea

• ClinicalTrials.gov Identifier: NCT00292344
• Recruitment Status: Completed
• First Posted: February 15, 2006
• Last Update Posted: April 20, 2009
• Sponsor: The University of Texas Health Science Center, Houston
• Collaborator: Bausch Health Americas, Inc.
• Information provided by: The University of Texas Health Science Center, Houston

Study Description

Brief Summary:

Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment.

Condition or disease	Intervention/treatment	Phase
Travelers' Diarrhea	Drug: Rifaximin and loperamide	Phase 4

Detailed Description:

During short-term study, adult U.S. students in Mexico (n = 310) with acute diarrhea (≥ 3 unformed stools with enteric symptoms) were enrolled in a double-blind, randomized trial wherein they were given rifaximin 200 mg three times a day for 3 days (R) (n = 102), loperamide 4 mg initially followed by 2 mg after each unformed stool not to exceed 8 mg/day for 2 days (L) (n = 104) or both drugs in the same dosage schedule (L/R) (n = 104). The major outcome parameter was time from initiation of therapy until passage of the last unformed stool before becoming well (TLUS).

Study Design

• Study Type: Interventional (Clinical Trial)
• Enrollment: 316 participants
• Allocation: Randomized
• Intervention Model: Single Group Assignment
• Masking: Double
• Primary Purpose: Treatment
• Official Title: Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea
• Study Start Date: June 2004
• Study Completion Date: August 2005

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

1. The major outcome parameter was time from initiation of therapy until passage of the last unformed stool before becoming well (TLUS).

Secondary Outcome Measures :

1. Secondary Outcome Variables:
2. 1. Time to passage of last unformed stool - standard definition of TLUS for antibiotics (18, 20) where wellness is declared at any time during 5 days regardless of later recurrence of continuing illness during the observation period;
3. 2. Number of unformed stools passed during two days of therapy;
4. 3. Number of unformed stools passed during the five days of study;
5. 4. Improvement in diarrhea (<half the number of daily entry unformed stools in 24 hours) by 24 hours and 48 hours;
6. 5. Treatment failure defined as: a. failure to achieve wellness during five days of study (achieve a TLUS-5 d); b. Deterioration during treatment and removed from further clinical evaluation, or, c. Occurrence of a relapse after achieving wellness during
7. 6. Occurrence of relapse during five day surveillance (occurrence of diarrhea after having a TLUS);
8. 7. TLUS in 48 hours - last unformed stool passed during the 48 hours that loperamide is being given (rapid symptomatic improvement);
9. 8. Number of days of moderate or severe enteric symptoms;
10. 9. Number of days passing any number of unformed stools plus any degree (mild, moderate or severe) of daily enteric symptoms (must have both present each day);
11. 10. Subjects global assessment of efficacy by day of study;
12. 11. Number of hours where schedule of activities were altered because of illness;
13. 12. Number of hours confined to bed because of diarrhea;
14. 13. Dropped from study due to adverse reaction;
15. 14. Number of doses of loperamide (or loperamide placebos) taken;
16. 15. Microbiologic eradication/failure.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Inclusion criteria include: IRB approval; signing of a consent form;18 years of age or older, providing of an unformed pre-treatment stool; females must be non-pregnant and not nursing.

Exclusion Criteria:

• Exclusion criteria include: diarrhea longer than 72 hours; moderate or severe dehydration, pregnancy or breast feeding, receipt of trimethoprim-sulfamethoxazole, azalide, doxycycline, or a fluoroquinolone in the past week; unstable medical condition; hypersensitivity to rifaximin or rifampin; fever (>100.6o F) or bloody diarrhea.

Contacts and Locations

Locations

Mexico

Universidad Autonoma de Guadalajara

Guadalajara, Jalisco, Mexico

University of Arizona, Colegio Guadalajara

Guadalajara, Jalisco, Mexico

University of San Diego at Iteso

Guadalajara, Jalisco, Mexico

Clinica Londres Morelos

Cuernavaca, Morelos, Mexico

Sponsors and Collaborators

The University of Texas Health Science Center, Houston

Bausch Health Americas, Inc.

Investigators

• Principal Investigator: Herbert L. DuPont, MD; The University of Texas Health Science Center, Houston

More Information

• ClinicalTrials.gov Identifier: NCT00292344
• Other Study ID Numbers: TRA-04-01
• First Posted: February 15, 2006
• Last Update Posted: April 20, 2009
• Last Verified: February 2006

Keywords provided by The University of Texas Health Science Center, Houston:

Travelers' diarrhea; rifaximin; loperamide; enterotoxigenic E. coli

Additional relevant MeSH terms:

Dysentery; Diarrhea; Signs and Symptoms, Digestive; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases; Rifaximin; Loperamide; Antidiarrheals; Anti-Bacterial Agents; Anti-Infective Agents; Gastrointestinal Agents